Highest-materiality recent filing
NexGel closes $1.21M private placement of convertible notes and warrants
Issued $1.21M aggregate principal amount of unsecured convertible notes at $0.60/share initial conversion price.
NEXGEL appoints two Sequence LifeScience leaders to board; Sequence led $5.5M financing
Brian J. Kieser (CEO) and Kevin M. Harris (COO) of Sequence LifeScience appointed to NEXGEL board effective May 6, 2026.
NexGel appoints Ian Blackman as CFO; Adam Drapczuk resigns as interim CFO
Ian Blackman appointed CFO effective April 27, 2026; CPA with over 30 years of finance leadership experience.
NexGel receives Nasdaq deficiency notice for bid price below $1; 180 days to cure
Closing bid price of common stock (NXGL) below $1.00 for 30 consecutive business days.
NexGel closes Celularity regenerative biomaterials acquisition; expects revenue to triple to ~$35M
Acquired Celularity's regenerative biomaterials portfolio for $13.3M ($8.3M cash + $5M convertible note); closed April 17, 2026.
NEXGEL signs $35M deal to buy Celularity's biomaterial portfolio; expects revenue to triple to ~$35M
Consideration up to $35M: $15M upfront plus $20M in milestone payments tied to net sales.
NexGel closes $1.8M Series A convertible note; up to $14.9M more for Q1 acquisition
Initial Series A convertible note raised $1,797,381 gross proceeds, bearing 10% interest (18% on default), convertible at $1.244/share with floor $0.2488.
Director Nachum Stein resigns from NexGel board effective February 2, 2026
Nachum Stein notified NexGel on January 29, 2026 of his resignation as Board member, effective February 2, 2026.
NexGel appoints Adam Drapczuk as Interim CFO, replacing Joseph McGuire effective Jan 1, 2026
Adam Drapczuk appointed Interim CFO effective Jan 1, 2026; succeeds Joseph F. McGuire terminated Dec 31, 2025.
NexGel spins off drug delivery program into NexGelRx; shareholders get 19.99% equity stake
NEXGEL spins off select Rx drug delivery assets into new entity NexGelRx; retains 19.99% non-dilutive equity stake.
NexGel cancels special meeting; drops proposal to increase authorized shares from 25M to 1B
Board voted on Nov 21, 2025 to cancel the Special Meeting scheduled for Nov 26, 2025.
NEXGEL Q3 revenue flat at $2.93M; net loss narrows to $0.65M
Net revenue $2.93M, virtually unchanged from $2.94M in Q3 2024.
NEXGEL Q2 revenue doubles to $2.88M, guided to $13M and positive EBITDA for FY2025
Revenue $2.88M, +100.3% YoY; gross margin 43.6% vs 20.3% YoY.
NEXGEL appoints Shutterstock CAO Steve Ciardiello, CPA, to its Board
Appointment effective July 31, 2025; Ciardiello also joins Audit Committee.
NEXGEL raises ~$1M in registered direct offering and private placement; warrants at $4.25
Registered direct offering of 413,044 shares at $2.30/share; gross proceeds ~$950,000.
NexGel furnishes new investor presentation; no material changes disclosed in filing
Began using a new investor presentation on July 31, 2025; furnished as Exhibit 99.1.
NEXGEL expands partnership with STADA; gets $1M non-dilutive capital for N.A. launches
Expansion includes digestive enzyme formulas and scar/stretch mark solutions for North America.
NexGel stockholders approve 780K share increase to incentive plan, elect directors
Stockholders approved Fourth Amendment to 2019 Long-Term Incentive Plan, increasing authorized shares by 780,000 to 1,651,429 total.
NexGel adopts investor presentation, no material new disclosures
New investor presentation used starting June 4, 2025; attached as Exhibit 99.1.
NexGel Q1 revenue $2.81M (+121% YoY); gross margin expands to 42.4% from 12.6%
Revenue $2.81M, up 121% YoY from $1.27M; guided Q1 slightly above prior outlook.
NexGel adopts new investor presentation; no material disclosures
Company began utilizing a new investor presentation on March 25, 2025.
NexGel Q4 revenue up 181% to $3.04M, guides 2025 revenue of $13M, positive EBITDA
Q4 revenue $3.04M (up 181% YoY); FY 2024 revenue $8.69M (up 112% YoY).
NEXGEL prelim Q4 rev ~$3M, FY2024 ~$8.6M (+100% YoY); guides FY2025 >$13M, cash flow positive
Preliminary Q4 2024 revenue ~$3.0M; full year ~$8.6M, representing >100% YoY growth for third consecutive year.
CEO Levy gets $375K salary, 150K options; McGuire named CFO
Adam Levy's 2025 employment agreement: base salary $375K (up $50K), 26,116 shares grant, 150K stock options at $3.829.
NEXGEL Q3 revenue record $2.94M (+141% YoY); gross margin expands to 43.6%
Net loss widened to $754K vs $552K Q3 2023, but improved from $979K Q2 2024; adjusted EBITDA loss narrowed to $347K.
NEXGEL raises ~$2M in registered direct offering of stock and warrants at $2.75/share
Offering of 727,272 common shares and warrants to buy 363,636 shares at $4.25; gross proceeds ~$2M.
NexGel adopts new investor presentation (Oct 2024); content not disclosed
Filed under Item 7.01 Regulation FD; presentation attached as Exhibit 99.1.
NexGel preannounces record Q3 2024 revenue of $2.85M, +133% YoY, +98% QoQ
Expected revenue $2.85M, up 133% YoY and 98% sequentially, beating prior $2.20M guidance by ~30%.
NEXGEL reports record Q2 revenue of $1.44M, net loss widens to $979K
Record Q2 revenue $1.44M, up 23.4% YoY; gross margin improved to 28.5% from 15.0%.
Gross proceeds of ~$1.11M from sale of 444K shares at $2.50/share and warrants exercisable at $4.25.
NexGel begins using new investor presentation as of July 29, 2024
New investor presentation adopted on July 29, 2024; content not disclosed in the 8-K.
NexGel reports preliminary Q2 revenue of $1.4M (+20% YoY); guides Q3 $2.2M, Q4 $2.6M
Preliminary Q2 2024 revenue of $1.4M, up ~20% YoY and ~10% sequentially.
NexGel stockholders elect five directors, ratify auditor at 2024 annual meeting
All five director nominees elected: Glassman (1,537,898 For), Henry (1,517,779), Levy (1,537,898), Stein (1,380,100), Zeldis (1,489,435).
NexGel acquires Silly George beauty brand for $600k cash+stock plus earn-out
Purchase price: $400k cash, $200k in NXGL common stock, and a 4-year net profit earn-out.
NEXGEL Q1 revenue $1.27M (+104% YoY); net loss $905K vs $807K YoY
Revenue increased 104% to $1.27M, driven by contract manufacturing (+58%) and branded products (+178%).
On May 6, 2026, Brian J. Kieser and Kevin M. Harris (collectively, the “ Board Appointees ”) were appointed to the board of directors
On May 6, 2026, Brian J. Kieser and Kevin M. Harris (collectively, the “ Board Appointees ”) were appointed to the board of directors
Mr. Blackman succeeds Mr. Drapczuk as the Company’s principal financial officer and principal accounting officer.
the Board of Directors of the Company (the “ Board ”) appointed Ian Blackman, age 58, as Chief Financial Officer of NexGel, Inc. (the “ Company ”), effective April 27, 2026.
Joseph F. McGuire Appointment as Chief Financial Officer
Max materiality 1.00 · Median 0.65 · Most common event other_material